Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Biologic therapy.

Duke University Medical Center, Durham, NC, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Durham, NC
Treatments:Chemotherapy, Biologic therapyHospital:Duke University Medical Center
Drugs:Journal:Link
Date:Jul 2011

Description:

Patients:
This study involved 32 patients with recurrent glioblastoma who had been previously treated with radiation therapy and temozolomide. The median patient age was 56 years and 59% were male.

Treatment:
Patients were treated with the chemotherapy agent temozolomide and the biologic therapy agent bevacizumab.

Toxicities:
There was one reported treatment-related death due to pneumonia. There was also one case of grade 4 pancreatitis. Grade 3 fatigue, diarrhea, and hemorrhoids were also reported.

Results:
The median progression-free survival and overall survival were 3.6 and 8.5 months, respectively.

Support:
This study was supported by Genetech, makers of bevacizumab (trade name: Avastin).

Correspondence: Dr. Annick Desjardins; email: [email protected]



Back